Page last updated: 2024-12-07

cellulose sulfate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cellulose sulfate is a synthetic anionic polysaccharide derivative of cellulose. It is produced by reacting cellulose with sulfuric acid. Cellulose sulfate is a white, odorless powder that is soluble in water. It has a number of applications, including as a thickener, emulsifier, and stabilizer in food, pharmaceuticals, and cosmetics. Cellulose sulfate is also used in the manufacture of paper, textiles, and other products. Cellulose sulfate is being studied for its potential use in a variety of biomedical applications, such as drug delivery, tissue engineering, and wound healing. For example, it is being investigated as a potential carrier for the delivery of anticancer drugs, as a scaffold for tissue engineering, and as a dressing for wounds. Cellulose sulfate is a promising material for biomedical applications because it is biocompatible, biodegradable, and has a number of desirable properties, such as its ability to form gels and its ability to interact with biological molecules. '

cellulose sulfate: RN given refers to cpd with unknown MF; vaginal gel being developed as both a contraceptive and blockage to STD somewhat like nonoxynol-9 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID98941
CHEMBL ID154126
CHEBI ID135742
SCHEMBL ID6394045
MeSH IDM0073824

Synonyms (17)

Synonym
brn 6075091
pyrrolidine, 1-(2-(4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2h-1-benzopyran-4-yl)phenoxy)ethyl)-, cis-
nsc 147956
cellulose sulfate
51423-20-2
nsc147956
nsc-147956
CHEBI:135742
CHEMBL154126
1-[2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl)phenoxy]ethyl]pyrrolidine
FT-0664458
SCHEMBL6394045
1-[2-[4-(2,2-dimethyl-7-methoxy-3-phenylchroman-4-yl)phenoxy]ethyl]pyrrolidine
levormeloxifene;centchroman;78994-24-8
BCP15758
DTXSID60860460
1-{2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2h-1-benzopyran-4-yl)phenoxy]ethyl}pyrrolidine

Research Excerpts

Overview

Cellulose sulfate is a semi-synthesized polysaccharide sulfate with a relatively simple chain structure and unique biological properties. It is a noncytotoxic antifertility agent that exhibits in vitro antimicrobial activity against sexually transmitted pathogens, including HIV.

ExcerptReferenceRelevance
"Cellulose sulfate (CelS), which is a GAG mimetic, was evaluated for its use in promoting neurite extension."( Investigation of glycosaminoglycan mimetic scaffolds for neurite growth.
Arinzeh, TL; Collins, G; Foston, M; Hashemi, S; Menezes, R; Meyer, J; Vincent, R, 2019
)
1.24
"Cellulose sulfate is a semi-synthesized polysaccharide sulfate with a relatively simple chain structure and unique biological properties and its biological applications have been explored in research and clinical trials."( Review on biomedical and bioengineering applications of cellulose sulfate.
Lin, D; Yao, S; Zhang, Q, 2015
)
1.38
"Cellulose sulfate (CS) is a noncytotoxic antifertility agent that exhibits in vitro antimicrobial activity against sexually transmitted pathogens, including HIV."( Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study.
Ballagh, SA; Brache, V; Callahan, M; Creinin, MD; Fichorova, RN; Hillier, SL; Lai, JJ; Mauck, C; Schwartz, JL; Weiner, DH, 2006
)
1.31
"Cellulose sulfate (CS) is a promising vaginal microbicide. "( Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men.
Buvé, A; Jespers, V; Van Damme, L, 2007
)
2.05
"Cellulose sulfate (CS) is an antimicrobial and contraceptive agent. "( A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe.
Cheng, H; Chipato, T; Depineres, T; Dhlakama, P; Hammond, N; Mauck, C; Napierala, S; Padian, N; Thompson, M; van der Straten, A, 2007
)
2.03
"Cellulose sulfate (CS) is a non-cytotoxic antifertility agent that also exhibits in vitro antimicrobial activity against sexually transmitted pathogens, including HIV."( Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study.
Archer, DF; Ballagh, S; Callahan, M; Creinin, M; Lai, JJ; Mauck, C; Pymar, H; Schwartz, J; Weiner, DH, 2001
)
1.29

Toxicity

A vaginal application of 6% cellulose sulfate twice daily for seven consecutive days is as safe and well tolerated as a similar regimen of K-Y Jelly.

ExcerptReferenceRelevance
" This biotest based on quenching the luminescence of bacteria under the action of a toxic agent is rapid and highly reproducible."( [Bioluminescent method of assessing the toxicity of colored substances in waste waters from celluose sulfate manufacture].
Gil', TA; Novikova, LN; Rudykh, AR; Stom, DI,
)
0.13
" Safety was assessed by symptoms and signs (including colposcopy) of genital irritation, review of adverse events, and by changes in vaginal health as assessed by microscopy."( Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
Ali, MM; Callahan, M; Chitlange, S; Hazari, K; Malonza, IM; Mirembe, F; Nakabiito, C; Odusoga, LO; Osinupebi, OA; Van Damme, L, 2005
)
0.58
"A vaginal application of 6% cellulose sulfate twice daily for seven consecutive days is as safe and well tolerated as a similar regimen of K-Y Jelly."( Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
Ali, MM; Callahan, M; Chitlange, S; Hazari, K; Malonza, IM; Mirembe, F; Nakabiito, C; Odusoga, LO; Osinupebi, OA; Van Damme, L, 2005
)
0.87
"CS gel was safe with no reported severe or life-threatening adverse events (AE)."( Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
Absalon, J; El-Sadr, WM; Gai, F; Hoesley, C; Justman, J; Kwiecien, A; Maslankowski, L; Mâsse, B; Mauck, C; Mayer, KH; Morrow, K; Soto-Torres, L, 2006
)
0.63
"CS was safe for twice-daily use for 14 days."( Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study.
Ballagh, SA; Brache, V; Callahan, M; Creinin, MD; Fichorova, RN; Hillier, SL; Lai, JJ; Mauck, C; Schwartz, JL; Weiner, DH, 2006
)
0.59
"Cellulose sulfate appeared safe when used for 6 months alone or with a diaphragm."( A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe.
Cheng, H; Chipato, T; Depineres, T; Dhlakama, P; Hammond, N; Mauck, C; Napierala, S; Padian, N; Thompson, M; van der Straten, A, 2007
)
2.03
" Endpoints included immune biomarkers in cervicovaginal lavage (CVL) and endocervical cytobrushes, inflammatory infiltrates in vaginal biopsies, epithelial integrity by naked eye, colposcopy, and histology, CVL anti-HIV activity, vaginal microflora, pH, and adverse events."( Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure.
Archer, DF; Callahan, MM; Chandra, N; Creinin, MD; Dezzutti, CS; Doncel, GF; Fichorova, RN; Hillier, SL; Lai, JJ; Mauck, CK; Schwartz, JL; Weiner, DH, 2013
)
0.39
" We compared changes generated with N9 and BZK treatment to the changes generated in response to tenofovir gel, a candidate microbicide that holds promise as a safe and effective microbicide."( New candidate biomarkers in the female genital tract to evaluate microbicide toxicity.
D'Andrea, A; Fields, S; Fong, J; Mirsalis, J; Rasoul, B; Shew, K; Song, B; Works, MG; Yiu, Y, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" Undoubtedly, the enteric dosage forms with naproxen can be considered as safer."( Gellan gum macrobeads loaded with naproxen: The impact of various naturally derived polymers on pH-dependent behavior.
Froelich, A; Kunstman, P; Milanowski, B; Osmałek, TZ; Skotnicki, M; Soból, M; Szybowicz, M, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
flavonoidsAny organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them.
etherAn organooxygen compound with formula ROR, where R is not hydrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.99530.035520.977089.1251AID504332
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
gemininHomo sapiens (human)Potency22.69190.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency28.69540.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID451833Displacement of [3H]estradiol from rat estrogen receptor by radiometric assay relative to estradiol2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of 2,3,4-triarylbenzopyran derivatives as SERM and therapeutic agent for breast cancer.
AID173474Estrogenic activity as percent of control at 100 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID184492Antiimplantation activity in sperm-positive female albino rats mated to coeval males of proven fertility1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID194107Anti-uterotrophic activity in immature rats at 5 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID196351Antiuterotrophic activity in immature rats at 5 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID197051Estrogenic activity in immature rats and assayed as uterine weight gain at 50 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID197049Estrogenic activity in immature rats and assayed as uterine weight gain at 100 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID194105Anti-uterotrophic activity in immature rats at 100 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID173605Effective dose for antiimplantation activity in male albino rats1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antifertility agents. 38. Effect of the side chain and its position on the activity of 3,4-diarylchromans.
AID451834Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of 2,3,4-triarylbenzopyran derivatives as SERM and therapeutic agent for breast cancer.
AID173477Estrogenic activity as percent of control at 500 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID195685Uterotrophic activity in rats relative to estradiol (E2 = 100%)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID189169Relative binding affinity for uterine cytosolic estrogen receptors of immature rats1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID197043Estrogenic activity in immature rats and assayed as uterine weight gain at 0.05 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID196350Antiuterotrophic activity in immature rats at 50 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID197040Anti-uterotrophic activity in immature rats at 50 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID197041Anti-uterotrophic activity in immature rats at 5 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID173472Estrogenic activity as percent of control at 0.5 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID173475Estrogenic activity as percent of control at 5 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID69538Relative binding affinity for uterine cytosol 17-beta-estradiol receptor obtained from immature Charles Foster rats1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antifertility agents. 38. Effect of the side chain and its position on the activity of 3,4-diarylchromans.
AID197050Estrogenic activity in immature rats and assayed as uterine weight gain at 5 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID173476Estrogenic activity as percent of control at 50 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID196349Antiuterotrophic activity in immature rats at 100 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID197047Estrogenic activity in immature rats and assayed as uterine weight gain at 0.05 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID343883Antiimplantation activity against Sprague-Dawley albino rat at 1 mg/kg, po administered for 1-5 days measured on day 10 of pregnancy relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis and in vivo evaluation of 11-substituted estradiol derivatives as anti-implantation agents.
AID197039Anti-uterotrophic activity in immature rats at 100 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID194106Anti-uterotrophic activity in immature rats at 50 ug1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID173469Estrogenic activity as percent of control at 0.05 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID451832Estrogenic antagonistic activity in bilaterally ovariectomized Sprague-Dawley rat assessed as inhibition of ethynylesterol-induced uterine weight at 10 mg/kg, po once daily for 3 days measured on day 31 of age2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of 2,3,4-triarylbenzopyran derivatives as SERM and therapeutic agent for breast cancer.
AID343882Antiimplantation activity against Sprague-Dawley albino rat at 10 mg/kg, po administered for 1-5 days measured on day 10 of pregnancy relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis and in vivo evaluation of 11-substituted estradiol derivatives as anti-implantation agents.
AID180231Effect on uterine weight gain in immature rats by subcutaneous dose; N-Nil1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antifertility agents. 38. Effect of the side chain and its position on the activity of 3,4-diarylchromans.
AID451835Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of 2,3,4-triarylbenzopyran derivatives as SERM and therapeutic agent for breast cancer.
AID197052Estrogenic activity in immature rats and assayed as uterine weight gain at 500 ug subcutaneous dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity.
AID180230Compound was evaluated in immature rats as assessed by uterine weight gain (subcutaneously)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Antifertility agents. 38. Effect of the side chain and its position on the activity of 3,4-diarylchromans.
AID451831Estrogenic agonistic activity in bilaterally ovariectomized Sprague-Dawley rat assessed as uterine weight gain at 10 mg/kg, po once daily for three days measured on day 31 of age2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Synthesis and biological evaluation of 2,3,4-triarylbenzopyran derivatives as SERM and therapeutic agent for breast cancer.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (152)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (15.13)18.7374
1990's12 (7.89)18.2507
2000's59 (38.82)29.6817
2010's47 (30.92)24.3611
2020's11 (7.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.87 (24.57)
Research Supply Index5.20 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index39.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (9.70%)5.53%
Reviews5 (3.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other144 (87.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]